Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q4 2022 Earnings Call Transcript

Abhi Srivastava: Yeah, Tom. So we are investing in multi-pronged manufacturing strategy to really cut down our manufacturing time. We are constantly investing in process development, closing the system, providing the automation in our manufacturing platform, And by doing so, we are very confident that we’ll be able to reduce the manufacturing time to the 15 days as we reach to the commercialization space.

Thomas Flaten: Sorry, sorry, go ahead.

Abhi Srivastava: And just wanted to highlight that how much cryopreservation has provided us the power of flexibility by utilizing that cryopreservation will be able to manufacture the better product and overall efficacy of the — what I’ll call overall quality of the bucket. (ph)

Kevin Boyle Senior: Thomas, just important I think to highlight here is one of the things that cryopreservation does, when fresh cells you had a patient that was ready to be infused immediately. So timing really mattered, right? Now the fact that we’re able to manufacture the cells ahead of time in this Phase 1 portion of the trial with the cryopreservation, whether it’s 26 days or 15 days, it’s still earlier in the patient’s journey where they’re not quite ready to be infused yet. So the time is less relevant at this stage. So we have the time to be able by the time, as Abhi said, when we hit commercial, it will be reduced. That will be very important. But as of right now, the timeframe taking the manufacturing to cells is less relevant because the cells will be frozen down and be available immediately when the patient is ready.

Thomas Flaten: Excellent. Appreciate it. Thank you guys.

Kevin Boyle Senior: Thank you, Thomas.

Operator: Thank you. And this does conclude today’s question-and-answer session. Ladies and gentlemen, this also does conclude today’s conference call. Thank you for participating. You may now disconnect. Everyone have a great day.